Get the Stockscreener App
1.52
5.00%
-0.08
Maxcyte Inc stock is traded at $1.52, with a volume of 1.18M.
It is down -5.00% in the last 24 hours and down -3.80% over the past month.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
See More
Previous Close:
$1.60
Open:
$1.61
24h Volume:
1.18M
Relative Volume:
1.24
Market Cap:
$162.14M
Revenue:
$45.44M
Net Income/Loss:
$-35.43M
P/E Ratio:
-4.4706
EPS:
-0.34
Net Cash Flow:
$-25.39M
1W Performance:
+3.40%
1M Performance:
-3.80%
6M Performance:
-33.04%
1Y Performance:
-64.98%
1-Day Range:
$1.50
$1.61
1-Week Range:
$1.49
$1.61
52-Week Range:
$1.26
$5.20
Maxcyte Inc Stock (MXCT) Company Profile
Name
Maxcyte Inc
Sector
Industry
Phone
301-517-5556
Address
9713 KEY WEST AVENUE,, ROCKVILLE
Compare MXCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
1.52 | 170.68M | 45.44M | -35.43M | -25.39M | -0.34 |
|
ABT
Abbott Laboratories
|
125.46 | 214.37B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
92.58 | 136.01B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.09 | 134.98B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
99.87 | 127.88B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.08 | 48.88B | 5.88B | 1.34B | 799.60M | 2.3489 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-25 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-07-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-22-25 | Initiated | Stephens | Overweight |
| Nov-29-23 | Initiated | Craig Hallum | Buy |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-24-21 | Initiated | BTIG Research | Buy |
| Aug-24-21 | Initiated | Cowen | Outperform |
| Aug-24-21 | Initiated | Stephens | Overweight |
| Aug-24-21 | Initiated | Stifel | Buy |
| Aug-24-21 | Initiated | Wedbush | Outperform |
| Aug-24-21 | Initiated | William Blair | Outperform |
View All
Maxcyte Inc Stock (MXCT) Latest News
Prepare Yourself for Liftoff: MaxCyte Inc (MXCT) - setenews.com
Healthy Upside Potential: MaxCyte Inc (MXCT) - setenews.com
Mirabella Financial Services LLP Has $14.39 Million Stock Position in MaxCyte, Inc. $MXCT - MarketBeat
How MaxCyte Inc. (MYE0) stock compares with market leadersWeekly Stock Report & Smart Swing Trading Techniques - Newser
Is MaxCyte Inc. (MYE0) stock attractive post correction2025 Top Gainers & Daily Price Action Insights - Newser
Can MaxCyte Inc. (MYE0) stock stage a strong rebound this quarterJuly 2025 Sector Moves & Short-Term Swing Trade Alerts - Newser
Is MaxCyte Inc. stock attractive for ETFsTrade Risk Summary & Consistent Return Strategy Ideas - Newser
Why analysts recommend MaxCyte Inc. (MYE0) stockJuly 2025 Trends & Weekly Setup with ROI Potential - Newser
Is MaxCyte Inc. (MYE0) stock dividend growth reliableAnalyst Upgrade & Stepwise Trade Execution Plans - Newser
MaxCyte drives CAR T manufacturing optimization using ExPERT system - Traders Union
Dividend Watch: Why Clearway Energy Inc. (NY4B) stock is upgraded to buyJuly 2025 Volume & Verified Technical Signals - BỘ NỘI VỤ
MaxCyte (MXCT) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO - Morningstar
Will MaxCyte Inc. stock attract more institutional investors - moha.gov.vn
The time has not yet come to remove your chips from the table: MaxCyte Inc (MXCT) - setenews.com
MaxCyte aims to optimize CAR T manufacturing with ExPERT system - Traders Union
MaxCyte (NASDAQ:MXCT) Stock Rating Upgraded by Wall Street Zen - Defense World
MaxCyte, Inc. (NASDAQ:MXCT) Receives Average Rating of "Hold" from Analysts - MarketBeat
MaxCyte: Building the Future of Cell and Gene Therapy Innovation - MSN
MXCT SEC FilingsMaxcyte 10-K, 10-Q, 8-K Forms - Stock Titan
What drives MaxCyte Inc MYE0 stock priceRSI Overbought/Oversold & Daily Tips From Top Market Analysts - earlytimes.in
How MaxCyte Inc. (MYE0) stock reacts to fiscal policiesJuly 2025 Market Mood & Safe Entry Point Alerts - newser.com
Can MaxCyte Inc. (MYE0) stock reach $200 price target2025 Major Catalysts & Weekly High Return Opportunities - newser.com
MaxCyte explores electroporation's role in cell therapy innovation - Traders Union
How MaxCyte Inc. (MYE0) stock behaves under inflation pressureEarnings Recap Summary & High Conviction Buy Zone Picks - newser.com
What Wall Street predicts for MaxCyte Inc. stock priceQuarterly Earnings Report & Risk Managed Investment Entry Signals - newser.com
MaxCyte drives cell engineering focus at Advanced Therapies USA - Traders Union
MaxCyte Announces Major Workforce Reduction Plan - MSN
Is MaxCyte Inc. stock a buy in volatile marketsJuly 2025 Weekly Recap & Reliable Intraday Trade Plans - newser.com
MaxCyte at Stephens Annual Investment Conference: Strategic Restructuring Amid Market Challenges By Investing.com - Investing.com Canada
Will MaxCyte Inc. stock split again soonTrade Risk Report & Daily Profit Maximizing Tips - newser.com
A Look at MaxCyte Inc (MXCT) Shares in the Recent Past Indicates Growth - Setenews
Is MaxCyte Inc. (MYE0) stock nearing a technical breakoutPortfolio Gains Summary & Community Consensus Picks - newser.com
MXCT: SecureDx integration and new product launches position for growth as industry rationalizes - TradingView — Track All Markets
What dividend safety rating applies to MaxCyte Inc. (MYE0) stockIPO Watch & Safe Capital Growth Trade Ideas - newser.com
How MaxCyte Inc. (MYE0) stock trades under stagflation2025 Performance Recap & Entry Point Strategy Guides - newser.com
FY2025 EPS Estimates for MaxCyte Boosted by William Blair - Defense World
Will MaxCyte Inc. (MYE0) stock see valuation expansionJuly 2025 Gainers & Weekly High Return Forecasts - newser.com
How buyback programs support MaxCyte Inc. (MYE0) stockTrade Analysis Summary & Weekly High Return Stock Opportunities - newser.com
What MACD signals say about MaxCyte Inc.July 2025 Patterns & Fast Exit and Entry Strategy Plans - newser.com
Maxcyte Inc Stock (MXCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Maxcyte Inc Stock (MXCT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Swirsky Douglas J | CHIEF FINANCIAL OFFICER |
Aug 13 '25 |
Buy |
1.29 |
50,000 |
64,500 |
161,811 |
| Masoud Maher | President and CEO |
Aug 13 '25 |
Buy |
1.37 |
75,000 |
102,915 |
175,000 |
| Erck Stanley C | Director |
Aug 13 '25 |
Buy |
1.37 |
100,000 |
137,220 |
398,328 |
| DOUGLAS RICHARD | Director |
Aug 13 '25 |
Buy |
1.39 |
80,000 |
111,040 |
230,577 |
| Brooke William W | Director |
Aug 13 '25 |
Buy |
1.29 |
50,000 |
64,500 |
150,879 |
0.52%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):